婴儿同时接种B群脑膜炎球菌(4CMenB)与C群脑膜炎球菌(MenC-CRM)疫苗的免疫原性与安全性:一项3b期随机对照试验
这项3b期随机对照试验将251名婴儿按1:1随机分组,分别同时接种4CMenB与MenC-CRM疫苗或单独接种MenC-CRM疫苗,在3、5月龄基础免疫和12月龄加强免疫后评估免疫原性与安全性。结果显示,同时接种组对MenC的应答非劣效于单独接种组,对MenB的应答达到充分性标准,同时接种组轻度至中度征集性不良事件发生率更高,但未发现安全性问题。
要点
- 同时接种组对MenC的应答在6月龄和13月龄非劣效于单独接种组。
- 同时接种组对MenB的应答达到充分性标准。
- 同时接种组轻度至中度征集性不良事件发生率更高,未发现安全性问题。
核心结论
- 婴儿同时接种MenC-CRM和4CMenB具有免疫原性,对MenC的应答非劣效于单独接种MenC-CRM,且对MenB显示出充分的免疫应答。
- 同时接种疫苗的反应原性更高,但未发现安全性问题。
研究设计与样本
- 3b期随机对照试验(NCT01339923),251名婴儿按1:1随机分为同时接种4CMenB和MenC-CRM组(第1组)或单独接种MenC-CRM组(第2组)。
- 在3月龄和5月龄接种,12月龄加强,并在3、5、7、12月龄接种肺炎球菌疫苗。
- 在3、6、12、13月龄检测脑膜炎球菌疫苗抗体应答。
主要发现
- 第1组对MenC的应答在6月龄和13月龄非劣效于第2组(率差的95%CI下限分别为-6.4%和-5.2%)。
- 第1组对MenB的应答达到充分性标准:6月龄针对fHbp、NadA、PorA菌株hSBA滴度≥1:4的婴儿百分比95%CI下限分别为92%、90%、89%;13月龄分别为97%、92%、93%。
- 第1组轻度至中度征集性不良事件发生率高于第2组;非征集性不良事件和严重不良事件发生率组间相似。
关键数值与推荐
- MenC应答非劣效标准:第1组与第2组hSBA滴度≥1:8的婴儿百分比差值的95%CI下限>-10%。
- MenB应答充分性标准:6月龄针对fHbp、NadA、PorA菌株hSBA滴度≥1:4的婴儿百分比95%CI下限≥70%,或13月龄≥75%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After implementation of routine infant MenC vaccination, MenB remains a serious cause of meningococcal disease, yet to be targeted by vaccination programs in several countries. This study (NCT01339923) investigated the immunogenicity and safety of MenC CRM-conjugated vaccine (MenC-CRM) concomitantly administered with MenB vaccine (4CMenB). METHODS: Infants (N=251) were randomised 1:1 to receive 4CMenB and MenC-CRM (Group 1) or MenC-CRM alone (Group 2) at 3 and 5months (M3, M5) and a booster at 12months of age (M12), and pneumococcal vaccine at M3, M5, M7, M12. Antibody responses to meningococcal vaccines were measured at M3, M6, M12, and M13. Non-inferiority of MenC-CRM response in Group 1 vs Group 2 was demonstrated at M6 and M13, if the lower limit of the 95% confidence interval (LL95%CI) of the difference in percentage of infants with hSBA titres ≥1:8 was >-10%. Sufficiency of MenB response was achieved if LL95%CI of the percentage of infants with hSBA titres ≥1:4 against fHbp, NadA and PorA strains was ≥70% at M6 or ≥75% at M13. Adverse events (AEs) were collected for 7days post-vaccination, and serious AEs (SAEs) and medically attended AEs throughout the study. RESULTS: Non-inferiority of MenC response in Group 1 vs Group 2 (LL95%CI -6.4% [M6]; -5.2% [M13]) and sufficiency of MenB response in Group 1 (LL95%CI 92%, 90%, 89% [M6]; 97%, 92%, 93% [M13] against fHbp, NadA, PorA, respectively) were demonstrated. Higher rates of mild to moderate solicited AEs were reported in Group 1. Unsolicited AEs and SAEs incidences were similar across groups. CONCLUSIONS: Concomitant administration of MenC-CRM and 4CMenB in infants was immunogenic, resulting in non-inferior responses against MenC compared to MenC-CRM alone and demonstration of sufficient immune response to MenB, after primary and booster vaccination. Reactogenicity was higher for concomitant vaccines administration, but no safety concerns were identified.
引用
- P Safadi MA, Martinon-Torres F, Weckx LY, et al. Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial. Vaccine. 2017. PMID: 28318767. doi:10.1016/j.vaccine.2017.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。